<DOC>
	<DOC>NCT00673231</DOC>
	<brief_summary>This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin</brief_summary>
	<brief_title>Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 Diabetes Patients with HbA1c ≥7.5% and ≤10.5% and who are on a stable insulin regimen of at least 30 IU of injectable insulin per day either without any other oral antidiabetic drug or with a stable dose of oral antidiabetic drugs Type 1 Diabetes Treatment with more than two additional oral antidiabetic drugs Moderate and severe renal (kidney) failure or dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>add on to insulin</keyword>
	<keyword>Oral AntiDiabetic</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>